


Spiriva Respimat (tiotropium bromide) - Drug Summary

Boehringer Ingelheim Pharmaceuticals, Inc.



WARNINGS/PRECAUTIONS

Not for relief of acute symptoms (eg, acute episodes of bronchospasm). Immediate hypersensitivity reactions may occur; d/c and consider alternative treatments if such a reaction occurs. Closely monitor patients w/ a history of hypersensitivity reactions to atropine, or its derivatives. May cause paradoxical bronchospasm; d/c and consider other treatments, and treat immediately w/ an inhaled, short-acting β_2 -agonist. Caution w/ narrowangle glaucoma; monitor for signs and symptoms. Caution w/ urinary retention; monitor for signs and symptoms, especially in patients w/ prostatic hyperplasia or bladder neck obstruction. Closely monitor for anticholinergic

effects in patients w/ moderate to severe renal impairment (CrCl <60mL/min).

ADVERSE REACTIONS

COPD: Pharyngitis, cough, dry mouth, sinusitis. **Asthma:** Pharyngitis, sinusitis, bronchitis, headache.

DRUG INTERACTIONS

Possible increase in anticholinergic adverse effects w/ other anticholinergic-containing drugs; avoid coadministration.

PREGNANCY AND LACTATION

Pregnancy: Category C. **Lactation:** Caution in nursing.

MECHANISM OF ACTION

Anticholinergic (long-acting) bronchodilator; exhibits effects through inhibition of M_3 -receptors at the smooth muscle, leading to bronchodilation.

PHARMACOKINETICS

Absorption: Absolute bioavailability (2-3%, oral sol); T_{max} =5-7 min. **Distribution:** (IV) V_d =32L/kg; plasma protein binding (72%). **Metabolism:** Liver (oxidation, conjugation) via CYP2D6 and 3A4. **Elimination:** Urine (74%, unchanged, IV); $T_{1/2}$ =25 hrs (COPD), 44 hrs (asthma).

ASSESSMENT

Assess for hypersensitivity to drug, atropine or its derivatives, narrow-angle glaucoma, urinary retention, prostatic hyperplasia, bladder neck obstruction, renal impairment, pregnancy/nursing status, and possible drug interactions.

MONITORING

Monitor for hypersensitivity reactions, paradoxical bronchospasm, narrow-angle glaucoma, and other adverse reactions. Monitor for urinary retention, especially in those w/ prostatic hyperplasia or bladder neck obstruction.

PATIENT COUNSELING

Advise to d/c if paradoxical bronchospasm occurs. Instruct to consult physician immediately if any signs/symptoms of narrow-angle glaucoma and urinary retention develop. Advise not to allow the aerosol cloud to enter into the eyes. Caution about engaging in activities such as driving a vehicle or operating appliances/machinery. Instruct asthma patients that the max benefits of therapy may only be apparent after 4-8 weeks of therapy. Inform that drug is not for immediate relief of breathing problems. Instruct to administer ud.

STORAGE

25°C (77°F); excursions permitted to 15-30°C (59-86°F). Avoid freezing. After assembly, discard the inhaler at the latest 3 months after 1st use or when the locking mechanism is engaged, whichever comes 1st.

Back to top

About Us | Help | Contact Us | Order Books | Report Adverse Events | Privacy Policy | Terms of Service

US-based MDs, DOs, NPs and PAs in full-time patient practice can register for free on PDR.net. PDR.net is to be used only as a reference aid. It is not intended to be a substitute for the exercise of professional judgment. You should confirm the information on the PDR.net site through independent sources and seek other professional guidance in all treatment and diagnosis decisions.

